These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9850097)

  • 1. MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats.
    Kam JL; Regimbald LH; Hilgers JH; Hoffman P; Krantz MJ; Longenecker BM; Hugh JC
    Cancer Res; 1998 Dec; 58(23):5577-81. PubMed ID: 9850097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer.
    Regimbald LH; Pilarski LM; Longenecker BM; Reddish MA; Zimmermann G; Hugh JC
    Cancer Res; 1996 Sep; 56(18):4244-9. PubMed ID: 8797599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study.
    Grinstead JS; Schuman JT; Campbell AP
    Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
    Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
    Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrimination of MUC1 mucins from other sialyl-Le(a)-carrying glycoproteins produced by colon carcinoma cells using a novel monoclonal antibody.
    Baeckström D; Nilsson O; Price MR; Lindholm L; Hansson GC
    Cancer Res; 1993 Feb; 53(4):755-61. PubMed ID: 7679050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and dynamic consequences of increasing repeats in a MUC1 peptide tumor antigen.
    Schuman JT; Grinstead JS; Apostolopoulos V; Campbell AP
    Biopolymers; 2005 Feb; 77(2):107-20. PubMed ID: 15635690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure/activity studies of the anti-MUC1 monoclonal antibody C595 and synthetic MUC1 mucin-core-related peptides and glycopeptides.
    Spencer DI; Missailidis S; Denton G; Murray A; Brady K; Matteis CI; Searle MS; Tendler SJ; Price MR
    Biospectroscopy; 1999; 5(2):79-91. PubMed ID: 10217327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses.
    Barratt-Boyes SM; Vlad A; Finn OJ
    Clin Cancer Res; 1999 Jul; 5(7):1918-24. PubMed ID: 10430099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1 initiates Src-CrkL-Rac1/Cdc42-mediated actin cytoskeletal protrusive motility after ligating intercellular adhesion molecule-1.
    Shen Q; Rahn JJ; Zhang J; Gunasekera N; Sun X; Shaw AR; Hendzel MJ; Hoffman P; Bernier A; Hugh JC
    Mol Cancer Res; 2008 Apr; 6(4):555-67. PubMed ID: 18403635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat.
    Tarp MA; Sørensen AL; Mandel U; Paulsen H; Burchell J; Taylor-Papadimitriou J; Clausen H
    Glycobiology; 2007 Feb; 17(2):197-209. PubMed ID: 17050588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMR solution structure of a potent cyclic nonapeptide inhibitor of ICAM-1-mediated leukocyte adhesion produced by homologous amino acid substitution.
    Sillerud LO; Burks EJ; Brown WM; Brown DC; Larson RS
    J Pept Res; 2004 Oct; 64(4):127-40. PubMed ID: 15357668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular biological analyses of mucin core proteins and their clinical application].
    Hinoda Y; Imai K
    Gan To Kagaku Ryoho; 1994 Feb; 21(2):150-6. PubMed ID: 8311484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New mucin core protein genes and their clinical application].
    Imai K
    Hokkaido Igaku Zasshi; 1996 Mar; 71(2):139-43. PubMed ID: 8641670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and antibody recognition of synthetic antigens from MUC1.
    Bánóczi Z; Mezõ G; Windberg E; Uray K; Majer Z; Hudecz F
    J Pept Sci; 2008 May; 14(5):610-6. PubMed ID: 17975847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation.
    Karsten U; Diotel C; Klich G; Paulsen H; Goletz S; Müller S; Hanisch FG
    Cancer Res; 1998 Jun; 58(12):2541-9. PubMed ID: 9635576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MUC1 mucin core protein binds to the domain 1 of ICAM-1.
    Hayashi T; Takahashi T; Motoya S; Ishida T; Itoh F; Adachi M; Hinoda Y; Imai K
    Digestion; 2001; 63 Suppl 1():87-92. PubMed ID: 11173916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
    Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB.
    Lin YC; Shun CT; Wu MS; Chen CC
    Clin Cancer Res; 2006 Dec; 12(23):7165-73. PubMed ID: 17145842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.